Ascletis Presents Phase III Results of Denifanstat for Acne at EADV 2025

Ascletis Presents Phase III Results of Denifanstat for Acne at EADV 2025

By, Admin 18 September 2025

Ascletis Pharma Inc. (HKEX: 1672) presented Phase III results of denifanstat (ASC40) in moderate to severe acne vulgaris at the EADV Congress 2025 in Paris.

The data were featured in the Late Breaking News sessions on September 17, 2025.

Oral Presentation Details

  • Title: First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in Acne Vulgaris: Results from a Phase III Randomised Placebo-Controlled Trial.
  • Presenter: Dr. Leihong (Flora) Xiang, Principal Investigator, Huashan Hospital, Fudan University.

The Phase III study was a randomized, double-blind, placebo-controlled, multicenter trial in China with 480 patients.

Participants received either 50 mg denifanstat once daily or placebo for 12 weeks, with a 1:1 randomization ratio. Baseline characteristics were balanced across groups.

Trial Endpoints

Primary endpoints:

  • Treatment success (IGA score 0 or 1, with ≥2-point improvement).
  • Percent reduction in total lesion count (TLC).
  • Percent reduction in inflammatory lesion count (ILC).

Key secondary endpoint:

  • Percent reduction in non-inflammatory lesion count (NILC).

Secondary endpoints:

  • Absolute reduction in TLC.
  • Absolute reduction in ILC.

Efficacy Results

Significant improvements appeared by Week 4 in treatment success, TLC, ILC, and NILC.

At Week 12, denifanstat (ASC40) met all primary, key secondary, and secondary endpoints (ITT analysis).

Table 1. Efficacy Results (Denifanstat vs. Placebo)

Endpoint

Denifanstat (%)

Placebo (%)

Difference

p-value

Treatment success

33.17

14.58

18.59

<0.0001

TLC Reduction

57.38

35.42

21.96

<0.0001

ILC reduction

63.45

43.21

20.24

<0.0001

NILC reduction

51.85

28.94

22.91

<0.0001

Absolute TLC reduction

58.25

36.17

22.08

<0.0001

Absolute ILC reduction

26.56

18.42

8.14

<0.0001

 

Safety and Tolerability

Denifanstat demonstrated a favorable safety profile after 12 weeks.

  • TEAEs: 58.6% (denifanstat) vs. 56.3% (placebo).
  • No TEAE category exceeded 10% incidence.
  • Only two categories crossed 5% incidence: dry skin (6.3% vs. 2.9%) and xerophthalmia (5.9% vs. 3.8%).
  • Most TEAEs were mild (Grade 1) or moderate (Grade 2).
  • No Grade 3/4 drug-related TEAEs.
  • No drug-related SAEs, deaths, or permanent discontinuations.

Next Steps

  • Pre-NDA consultation with China’s NMPA is ongoing, with encouraging feedback.
  • NDA submission for acne treatment is planned following consultation.

Leadership Commentary

“Denifanstat represents a new mechanism for acne treatment,” said Dr. Jinzi Jason Wu, Founder, Chairman, and CEO of Ascletis.

“It achieved statistically significant and clinically meaningful results across all endpoints, with a favorable safety profile.”

About Denifanstat (ASC40)

  • A first-in-class fatty acid synthase (FASN) inhibitor.
  • Licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive Greater China rights.
  • Designed as a once-daily oral tablet for acne vulgaris.

About Ascletis Pharma Inc.

Ascletis is a biotechnology company developing best-in-class and first-in-class drugs for metabolic diseases.

Key platforms:

  • AISBDD (AI-Assisted Structure-Based Drug Discovery).
  • ULAP (Ultra-Long-Acting Platform).

Lead program: ASC30, an oral and injectable GLP-1R agonist for chronic weight management.

Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!